Ken Griffin Bio N Tech Se Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $21.5 Million - $34.3 Million	274,900 Added 132.61%	482,200 $57.3 Million
Q2 2024 Aug 14, 2024	BUY	$80.36 - $102.87 $6.53 Million - $8.36 Million	81,300 Added 64.52%	207,300 $16.7 Million
Q1 2024 May 15, 2024	SELL	$88.96 - $112.35 $8.19 Million - $10.3 Million	-92,100 Reduced 42.23%	126,000 $11.6 Million
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $3.5 Million - $4.34 Million	38,500 Added 21.44%	218,100 $23 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $2.69 Million - $3.41 Million	-27,300 Reduced 13.19%	179,600 $19.5 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $266,708 - $337,116	2,600 Added 1.27%	206,900 $22.3 Million
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $38.1 Million - $47.7 Million	-310,700 Reduced 60.33%	204,300 $25.4 Million
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $1.72 Million - $2.7 Million	14,500 Added 2.9%	515,000 $77.4 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $27.3 Million - $39.2 Million	-214,000 Reduced 29.95%	500,500 $67.5 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.7B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.